Acute Peanut Consumption Alters Postprandial Lipids and Vascular Responses in Healthy Overweight or Obese Men¹–³

Xiaoran Liu,⁴ Alison M Hill,⁴,⁶ Sheila G West,⁶,⁶ Rachel M Gabauer,⁴ Cindy E McCrea,⁴,⁵ Jennifer A Fleming,⁴ and Penny M Kris-Etherton⁴*

Departments of ⁴Nutritional Sciences and ⁵Biobehavioral Health, The Pennsylvania State University, State College, PA; and ⁶School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia

Abstract

Background: Postprandial hyperlipidemia is associated with impaired endothelial function. Peanut consumption favorably affects the lipid and lipoprotein profile; however, the effects on endothelial function remain unclear.

Objective: The purpose of the study was to evaluate the effects of acute peanut consumption as part of a high-fat meal on postprandial endothelial function.

Methods: We conducted a randomized, controlled, crossover postprandial study to evaluate the effect of acute peanut consumption on postprandial lipids and endothelial function as assessed by flow-mediated dilatation (FMD) of the brachial artery in 15 healthy overweight or obese men [mean age: 26.7 y; mean body mass index (in kg/m²): 31.4]. Participants consumed, in a randomized order, a peanut meal containing 3 ounces (85 g) ground peanuts (1198 kcal; 40.0% carbohydrate, 47.7% fat, 19.4% saturated fat, 13.2% protein) and a control meal matched for energy and macronutrient content. Meals were in the form of a shake, scheduled 1 wk apart. Lipids, lipoproteins, glucose, and insulin were measured at baseline (0 min) and at 30, 60, 120, and 240 min after shake consumption. FMD was measured at baseline and at 240 min.

Results: Acute peanut consumption blunted the serum triglyceride (TG) response 120 and 240 min after consumption compared with the control meal (means ± SEMs—120 min: 188.9 ± 19.4 compared with 197.5 ± 20.7 mg/dL; 240 min: 189.9 ± 24.3 compared with 197.3 ± 18.4 mg/dL; P < 0.05 for both). Total, LDL, and HDL cholesterol and glucose and insulin responses were similar between the test meals. Compared with baseline, only the control meal significantly decreased FMD at 240 min (control: −1.2% ± 0.5%; P = 0.029; peanut: −0.6% ± 0.5%; P = 0.3). Participants with higher baseline total (>150 mg/dL) and LDL (>100 mg/dL)-cholesterol concentrations showed a significant decrease in FMD after the control meal (−1.8%, P = 0.017; −2.0%, P = 0.038), whereas the peanut meal maintained endothelial function in all participants irrespective of total- and LDL-cholesterol concentrations.

Conclusion: The inclusion of 85 g peanuts (3 ounces) as part of a high-fat meal improved the postprandial TG response and preserved endothelial function in healthy overweight or obese men. This trial was registered at clinicaltrials.gov as NCT01405300. J Nutr 2017;147:835–40.

Keywords: peanuts, nuts, postprandial responses, triglycerides, vascular function, overweight

Introduction

Cardiovascular disease (CVD)⁷ remains the leading cause of morbidity and mortality in the United States and globally. Several prospective studies have shown that the postprandial increase in nonfasting serum TGs increases the risk of atherosclerosis and ischemic stroke and is an independent risk factor for coronary artery disease (1–4). Evidence from the Women’s Health Study, a prospective study in 26,509 participants followed for a...
median of 11.4 y, reported that TGs measured 2–4 h after the last meal was a stronger predictor of events than were fasting TG concentrations (5). In addition, postprandial hypertriglyceridemia is involved in proinflammatory cytokine production and oxidative stress, thereby impairing vascular endothelial function, which also contributes to increased CVD risk (6–8).

Nuts contain many bioactive compounds with cardiometabolic benefits. Epidemiologic evidence from 3 large cohort studies (total n = 206,029) showed that nut and peanut consumption was inversely associated with total mortality (9). In the Nurses’ Health Study, the consumption of peanuts ≥2 times/wk led to a 34% reduction in relative risk of coronary artery disease (10). Peanuts are a popular snack in the United States and a source of unsaturated FAs, plant protein, and bioactive compounds (resveratrol, arginine, vitamin E, magnesium, fiber, and other antioxidants) (11, 12). Moderate [1–1.5 ounces/d (28–42 g/dl)] consumption of peanuts has been shown to improve glucose metabolism (13, 14) and the blood lipid and lipoprotein profile (15), with no increase in body weight (16). A recent clinical study in obese men showed that acute consumption of conventional peanuts and high-oleic peanuts (56 g, providing 25% of total energy) attenuated postprandial inflammatory and insulin responses compared with a control meal with no peanuts (17).

The cardioprotective effects of nuts are also thought to be achieved by maintaining endothelial function. Endothelial dysfunction is a precursor for atherosclerosis and an independent predictor of cardiac events (18). Endothelial dysfunction can limit the production and/or availability of NO, leading to impaired vasodilation (18). A previous study reported that the consumption of an ad libitum diet that included 56 g (366 kcal) walnuts/d for 8 wk improved endothelial function measured by flow-mediated dilatation (FMD) compared with a control diet without walnuts (change in FMD: 5.9% ± 3.3% compared with 3.6% ± 3.3%; P = 0.04) (20).

Postprandial hyperglycemia and hyperlipemia can initiate a cascade of biochemical events that lead to endothelial dysfunction (21). With the evidence we have to date that peanuts improve postprandial glucose (22, 23), lipid (17), and inflammatory (17) responses, it is possible that acute peanut consumption may improve vascular responses. However, there is limited evidence about whether peanut consumption affects postprandial vascular function. Therefore, in the present study we evaluated the effect of acute peanut consumption as part of a high-fat meal on postprandial vascular function, plasma glucose, insulin, and lipid and lipoprotein profiles. We hypothesized that acute peanut consumption would result in an improved lipid and lipoprotein profile and vascular function as assessed by FMD, a commonly used noninvasive assessment of vascular endothelial function.

### Methods

**Participants.** We recruited generally healthy, overweight or obese [BMI (in kg/m²) 28–39] men (to avoid hormone cycle effects on vascular function in women) between 20 and 65 y of age, with fasting TGs <350 mg/dl, LDL cholesterol <160 mg/dl, glucose <99 mg/dl, and blood pressure ≤140/90 mm Hg. Participants were free of diabetes, CVD, kidney disease, and other metabolic diseases. The study was approved by the Ethics Committee of The Pennsylvania State University and carried out in accordance with the Helsinki Declaration (clinicaltrials.gov, NCT01405300).

**Study design.** A randomized crossover trial was conducted. Participants were evaluated on 2 occasions separated by a washout period of a minimum of 7 d between interventions. Participants were randomly assigned to consume the control or peanut shake during visit 1 and the alternate shake was consumed during visit 2. On each occasion, fasting (10–12 h) blood samples were collected at baseline (t = 0 min) and then at 30, 60, 120, and 240 min after the ingestion of either a control shake or a peanut shake (consumed within 15 min). Participants were asked not to consume alcohol 48 h before the blood draw and to avoid vigorous exercise 2 h before the blood draw. FMD and blood pressure were measured at baseline (t = 0 min) and at 240 min.

**Nutrient profile and composition of the peanut and control shakes.** The nutrient profile of the test shakes is presented in Table 1. The control and peanut shakes were matched for macronutrient content. The control shake provided 24.8% carbohydrate, 64.7% fat (27.6% SFAs, 26.0% MUFAs, 11.1% PUFAs), 8.2% fiber, and 1198 kcal.

**Table 2** Anthropometric and metabolic characteristics of the men at screening

| Clinical measurements | Value |
|-----------------------|-------|
| Age, y                | 26.7 ± 1.6 |
| Weight, kg            | 100.0 ± 3.7 |
| BMI, kg/m²            | 31.4 ± 0.8 |
| SBP, mm Hg            | 125 ± 2 |
| DBP, mm Hg            | 83 ± 1 |
| Serum biochemistry    |       |
| Glucose, mg/dl        | 92.5 ± 0.7 |
| Total cholesterol, mg/dl | 159.7 ± 7.1 |
| HDL cholesterol, mg/dl | 42.4 ± 1.9 |
| LDL cholesterol, mg/dl | 99.1 ± 6.4 |
| TGs, mg/dl            | 90.6 ± 8.9 |
| TG-to-HDL-cholesterol ratio | 2.26 ± 1.15 |

1 Provided 3.0 ounces of ground peanuts with skins.

2 Abbreviations used: CVD, cardiovascular disease; FMD, flow-mediated dilatation; IAUC, incremental AUC; TC, total cholesterol.

3 Values are means ± SEMs. n = 15. DBP, diastolic blood pressure; SBP, systolic blood pressure.
26.0% MUFA, 11.1% PUFAs), 8.4% protein, 8.2 g fiber, and 1229 kcal. The peanut shake provided 25.9% carbohydrate, 66.2% fat (28.2% SFAs, 26.7 MUFA, 11.3% PUFAs), 8.5% protein, 8.2 g fiber, and 1198 kcal. The ingredient composition of the test shakes is presented in Table 1. Sunflower oil, safflower oil, powdered egg white, and fiber were used in the control shake to match the nutrient profile of 3 ounces (85 g) of peanuts. The amount of whipping cream and glucose in the peanut and control shakes was adjusted to ensure that all shakes were matched for carbohydrate and SFA contents. The control shake provided 34.8 g glucose, 150 g heavy whipping cream, 39 g chocolate syrup, 20 g sunflower oil, 17 g safflower oil, 27 g powered egg white, and 9.6 g fiber supplement (Benefiber; Novartis Consumer Health, Inc.). The peanut shake provided 34.8 g glucose, 137 g heavy whipping cream, 39 g chocolate syrup, and 85 g peanuts (3.0 ounces) ground peanuts with skins. Ingredients were blended with 150 g water and 60 g crushed ice in a Vitamix blender (Vita-Mix Corporation).

**Blood sampling.** A flexible catheter was inserted in the antecubital vein of the left arm, and blood samples were collected into evacuated tubes. Blood samples were collected in the fasted state (0 min) and at 30, 60, 120, and 240 min after consumption of the test meals. Serum samples were sent to Quest Diagnostics (Chem 24 panel; Quest Diagnostics) for analysis. Lipids and lipoproteins, glucose, insulin, and C-reactive protein were assayed at all time points.

**FMD.** Participants were asked to lie down for 15 min before the FMD assessment. Endothelial function was assessed by FMD with high-frequency ultrasound in a quiet, temperature-controlled room (21–24°C). Longitudinal images of the brachial artery 3–10 cm above the elbow of the right arm were acquired with external B mode ultrasound imaging (Acuson Aspen 128XP equipped with a 10-MHz linear array transducer; Acuson) and recorded during the following procedure: baseline (1 min), arterial occlusion (5 min) via inflation of a cuff on the forearm (distal to the segment being imaged) set at 250 mm Hg (Hokanson), and reactive hyperemia (2 min). Images were graded by using R-wave detection so that scans were assessed at the end of diastole. Two independent, blinded technicians used automated edge detection software (Brachial Analyzer; MIA) to quantify artery diameter continuously throughout the test. Resting diameters were the average of all images collected over the 1-min baseline period. Peak artery diameter was determined as the largest diameter recorded in the 2-min reactive hyperemia segment. The reported FMD score was calculated as the percentage change from resting arterial diameter to peak reactive hyperemia diameter. Scores presented are the average of the 2 technicians’ scores.

**Statistical analyses.** Statistical analysis was performed by using SAS (version 9.2; SAS Institute). The mixed-models procedure (PROC MIXED) was used to test the effects of treatment, time, and treatment by time interactions on each outcome. Subject was included as a random effect, and the remaining factors were fixed effects. Tukey-Kramer–adjusted P values were used for post hoc comparisons. The 4-h incremental AUC (IAUC) of postprandial concentrations of TGs, glucose, and insulin were analyzed by using a mixed model with treatment as a fixed effect. Changes were calculated by using values from the 240-min time point minus the baseline value (0 min).

As part of a secondary analysis, we categorized participants into 2 groups on the basis of their baseline total cholesterol (TC) concentrations at 150 mg/dL (mean of baseline TC) and baseline LDL-cholesterol concentration at 100 mg/dL (optimal LDL-cholesterol concentration: ≤100 mg/dL). For this stratification, we determined baseline concentrations to be the value taken at 0 min on the first day of testing. Baseline lipid concentrations were added as a categorical variable to the mixed model as a fixed effect to determine whether participants initially presenting with elevated cholesterol responded differently to peanut and control meals than did participants with lower baseline cholesterol concentrations. Means are reported as least-squares means ± SEs. A histogram and residual plots were used to verify normality of data. The study sample size was estimated with power set to 0.90 and α set to 0.05, which predicted a sample size of 15 participants to detect a 1% change in FMD (24).

### Table 1. Serum glucose, insulin, lipid, and lipoprotein responses to the control and peanut test meals in overweight or obese men

| Meal Type | 0 min | 30 min | 60 min | 120 min | 240 min |
|-----------|-------|--------|--------|---------|---------|
| **Glucose, mg/dL** |       |        |        |         |         |
| Control    | 88.7  | 89.3   | 89.7   | 89.5    | 89.7    |
| Peanut     | 88.7  | 89.2   | 89.8   | 89.8    | 89.7    |
| **Insulin, μU/mL** |       |        |        |         |         |
| Control    | 6.3   | 6.2    | 6.3    | 6.4     | 6.4     |
| Peanut     | 6.3   | 6.4    | 6.4    | 6.4     | 6.4     |
| **LDL-C, mmol/L** |       |        |        |         |         |
| Control    | 3.7   | 3.7    | 3.7    | 3.7     | 3.7     |
| Peanut     | 3.7   | 3.7    | 3.7    | 3.7     | 3.7     |
| **HDL-C, mmol/L** |       |        |        |         |         |
| Control    | 1.4   | 1.4    | 1.4    | 1.4     | 1.4     |
| Peanut     | 1.4   | 1.4    | 1.4    | 1.4     | 1.4     |
| **CRP, mg/dL** |       |        |        |         |         |
| Control    | 0.4   | 0.4    | 0.4    | 0.4     | 0.4     |
| Peanut     | 0.4   | 0.4    | 0.4    | 0.4     | 0.4     |
| **Total cholesterol, mg/dL** |       |        |        |         |         |
| Control    | 187   | 187    | 187    | 187     | 187     |
| Peanut     | 187   | 187    | 187    | 187     | 187     |

**Note.** Values are means ± SEMs. n = 15. "Different from the control meal at that time, P < 0.05. Within meal, means in a row with different superscript letters differ, P < 0.05. Unlabeled means are intermediate and not significantly different. CRP, C-reactive protein; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol.
**Results**

Participants and baseline characteristics. Fifteen nonsmoking male participants met all of the inclusion criteria and completed the study. None of the enrolled participants withdrew from the study. Participant baseline characteristics are presented in Table 2. In the present study, 40% of participants were overweight and 60% were obese.

Postprandial insulin, glucose, and lipids. Postprandial glucose, insulin, lipid, and lipoprotein concentrations in response to the test meals are presented in Table 3. A mixed linear model showed a treatment by time interaction for TGs ($P < 0.0001$). Both control and peanut meals increased postprandial TGs after 60 min of ingestion compared with baseline ($P < 0.05$ for both treatments). Peak TG responses to the 2 treatments were observed at 120 and 240 min ($P < 0.05$ for both treatments compared with baseline). At these time points, postprandial changes in plasma TG concentrations were greater ($P = 0.033$) after the control meal than after the peanut meal (Figure 1). The postprandial changes in plasma TG concentrations were also calculated as iAUCs. There was a 31.9% reduction in the TG iAUC after consumption of the peanut meal compared with the control meal ($P = 0.047$).

The TG-to-HDL-cholesterol ratio was used as a surrogate marker for insulin resistance (25). At 120 and 240 min, there was a trend for an increased TG-to-HDL-cholesterol ratio in response to the control meal compared with the peanut meal ($P = 0.09$). There were no treatment, time, or treatment-by-time interactions for TC, LDL cholesterol, or HDL cholesterol. As expected, glucose and insulin increased immediately after shake consumption (effect of time, $P < 0.001$), but no difference between treatments was observed.

Endothelial function. The control shake significantly reduced FMD by 1.2% at 240 min postconsumption compared with baseline ($P = 0.029$). There were no significant differences in FMD between baseline and 240 min postconsumption of the peanut shake (Figure 2). Baseline (0 min) cholesterol concentration predicted change in FMD. Participants with higher baseline TC concentrations (>150.0 mg/dL; $n = 9$) showed a significant decrease in FMD ($−1.8\%$; $P = 0.017$) 240 min after consumption of the control meal compared with baseline (Figure 3A). In contrast, FMD in response to the peanut meal remained unchanged in participants with both lower and higher baseline TC concentrations. Similar results were observed in participants with a higher baseline LDL-cholesterol concentration. Participants ($n = 6$) with a higher baseline LDL-cholesterol concentration ($>100$ mg/dL) showed a significant decrease in FMD ($−2.0\%$; $P = 0.038$) 240 min after the control meal (Figure 3B). Furthermore, the peanut meal did not decrease FMD compared with baseline in participants, irrespective of baseline LDL cholesterol concentration.

Discussion

In the present study, we assessed the effects of peanut consumption on metabolic responses and endothelial function in generally healthy overweight or obese men. Acute peanut consumption attenuated postprandial TG responses (31.9% reduction in TG iAUC) compared with a calorie and macronutrient-matched control meal. We showed that acute consumption of 3.0 ounces of peanuts as part of a high-fat meal significantly decreased endothelial function, particularly in participants with unfavorable baseline lipid profiles. In addition, these findings suggest that the inclusion of peanuts in the context of a high-fat meal may have favorable postprandial cardiometabolic effects.

Most individuals spend the majority of their nonsleeping hours in a postprandial state. Postprandial lipemia, a well-recognized risk factor for atherosclerosis, is associated with impaired endothelial function. During the postprandial period, an increase in TG-rich lipoproteins after a high-fat load increases oxidative stress. This resulting reduced NO bioavailability leads to endothelial dysfunction, which is indicated by a suppressed FMD response (26). Previous studies have shown that increases in postprandial TG-rich lipoproteins after a high-fat meal temporarily impair endothelial function in young ($23 \pm 2$ y) participants (27, 28). In the present study, the consumption of a high-fat control meal significantly decreased endothelial function, whereas it was maintained after the consumption of a macronutrient-matched meal with peanuts, and was accompanied by a blunted postprandial TG response. These findings suggest that peanut consumption preserves endothelial function in the presence of postprandial TG-rich lipoprotein increases, which may be related to a reduction in oxidative stress. We hasten
peanuts were provided to the participants, which provided in hypercholesterolemic young adults (31). In our study, 85 g (7 g, 3 times/d for 4 wk) improved endothelial dysfunction 24 wk improved the nutrient profile of the diet (increased unsaturated fat, α-tocopherol, niacin, and magnesium) and reduced body weight in participants with type 2 diabetes. Each kilogram of weight loss was associated with a 0.11-mmol/L reduction in fasting blood glucose and a 0.07% reduction in glycated hemoglobin (32). Moreover, peanuts (including peanut skins) are a source of phenolic compounds that have high antioxidant capacity, which may prevent endothelial damage by blunting postprandial oxidative reactions associated with a high-fat meal. The phenolic compounds in peanuts and nuts may also contribute to an anti-inflammatory postprandial response (33). There is evidence that postprandial inflammation and oxidative stress can exaggerate postprandial lipemia, which leads to vascular dysfunction and damage (34). Moreira Alves et al. (17) reported that acute consumption of 56 g peanuts (with skins) significantly reduced the postprandial inflammatory biomarkers TNF-α and IL-10 3 h after consumption in overweight men. Thus, the bioactive compounds in peanuts may attenuate inflammation and the resulting oxidative stress (caused by meals high in SFAs), thereby benefiting endothelial health, especially in the postprandial state.

This cardioprotective effect may be due to the bioactive compounds in peanuts and peanut skins. For example, NO is an important vasodilator that is synthesized from L-arginine in endothelial cells (29). Peanuts are a rich source of L-arginine, which reflects their high protein content (25% of total energy) (30). Dietary L-arginine could enhance NO synthesis and protect the endothelium against postprandial oxidative damage. Marchesi et al. (24) reported that 10-d administration of a low-dose of L-arginine (6 g/d) attenuated postprandial endothelial dysfunction in young healthy men. Oral L-arginine supplementation (7 g, 3 times/d for 4 wk) improved endothelial dysfunction in hypercholesterolemic young adults (31). In our study, 85 g peanuts were provided to the participants, which provided 2.74 g L-arginine.

In addition to L-arginine, other bioactive compounds in peanuts may offer other cardioprotective effects. Wien et al. (32) reported that the daily consumption of peanuts (46 g/d) over 24 wk improved the nutrient profile of the diet (increased unsaturated fat, α-tocopherol, niacin, and magnesium) and reduced body weight in participants with type 2 diabetes. Each kilogram of weight loss was associated with a 0.11-mmol/L reduction in to add that other mechanisms may be involved in mediating this effect, and additional research is needed to clarify this. This cardioprotective effect may be due to the bioactive compounds in peanuts and peanut skins. For example, NO is an important vasodilator that is synthesized from L-arginine in endothelial cells (29). Peanuts are a rich source of L-arginine, which reflects their high protein content (25% of total energy) (30). Dietary L-arginine could enhance NO synthesis and protect the endothelium against postprandial oxidative damage. Marchesi et al. (24) reported that 10-d administration of a low-dose of L-arginine (6 g/d) attenuated postprandial endothelial dysfunction in young healthy men. Oral L-arginine supplementation (7 g, 3 times/d for 4 wk) improved endothelial dysfunction in hypercholesterolemic young adults (31). In our study, 85 g peanuts were provided to the participants, which provided 2.74 g L-arginine.

In conclusion, the acute consumption of 3.0 ounces (85 g) of peanuts as a part of a high-fat meal reduced the postprandial TG response and maintained endothelial function in overweight and obese men, particularly in those who were at greater cardiometabolic risk due to elevated baseline TC and LDL-cholesterol concentrations. Therefore, frequent consumption of peanuts.

FIGURE 3  FMD responses of overweight or obese men by baseline TC (A) or LDL cholesterol (B) concentration 4 h after the control and peanut test meals. Values are least-squares means ± SEMs. *Different from 0 min, P < 0.05. FMD, flow-mediated dilatation; LDL-C, LDL cholesterol; TC, total cholesterol.
may improve CVD risk via mechanisms that involve postprandial cardiometabolic responses, including those that affect vascular function.

Acknowledgments
We thank Ann Skulas-Ray for her contributions to the study design. AMH, SGW, and PMK-E designed the research; XL, RMG, and JAF conducted the research; XL and CEM performed the statistical analysis; and XL and PMK-E wrote the manuscript. All authors read and approved the final manuscript.

References
1. Ansar S, Koska J, Reaven PD. Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins. Cardiovasc Diabetol 2011;10:61.
2. Freiberg JJ, Tybjærg-Hansen A, Jensen JS, Nordestgaard BG. Non-fasting triglycerides and risk of ischemic stroke in the general population. JAMA 2008;300:2142–52.
3. Nordestgaard BG, Benn M, Schnoor P, Tybjærg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007;298:293–308.
4. Langsted A, Freiberg JJ, Tybjærg-Hansen A, Schnoor P, Jensen GB, Nordestgaard BG. Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow-up. J Intern Med 2011;270:65–75.
5. Bansl S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker P. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007;298:309–16.
6. Nakamura K, Miyoshi T, Yonuko K, Ito H. Postprandial hyperlipidemia as a potential residual risk factor. J Cardiovasc Med 2016;6:735–9.
7. van Oostrom AJ, Sijmonsma TP, Verseyden C, Jansen EH, de Koning EJ. Fasting hypertriglyceridemia subjects: molecular mechanisms and gene expression studies. Atherosclerosis 2007;193:321–7.
8. Luu HN, Blot WJ, Xiang YB, Cai H, Wang P, Oda K, Sabate J. Pecans acutely increase plasma postprandial antioxidant capacity and decrease LDL oxidation in humans. J Nutr 2011;141:1536–42.
9. Palmer RM, Rees DD, Ashton DS, Moncada S. L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun 1988;153(2):397–402.
10. van Oostrom AJ, Sijmonsma TP, Verseyden C, Jansen EH, de Koning EJ. Fastin